Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.99 -0.09 (-0.17%)

Streaming Delayed Price Updated: 1:27 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

34 35 Next >

Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates ↗

December 12, 2022

Via Benzinga

Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A

December 12, 2022

From Spark Therapeutics, Inc.

Via GlobeNewswire

Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma

December 12, 2022

From Genentech

Via Business Wire

Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12 ↗

December 12, 2022

Reuters Broadcom's Vmware Draws More Regulatory Attention, This Time From EU

Via Benzinga

After 16 Years, Roche's Pharma Division Head Decides To Step Down ↗

December 12, 2022

Via Benzinga

Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022

December 11, 2022

From Genentech

Via Business Wire

Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth

December 11, 2022

From Genentech

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

3 Hot Stocks That Could Live Up to Their Lofty Valuations ↗

December 08, 2022

These companies have long runways of growth ahead

Via The Motley Fool

Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗

December 07, 2022

Via Benzinga

Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors ↗

December 02, 2022

Food and Drug Administration decisions and advisory committee verdicts slated for November were mostly positive. New molecular entity approvals so far this year trail 2021’s tally by about 35%.

Via Benzinga

Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up

December 01, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug...

Via FinancialNewsMedia

Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges ↗

November 28, 2022

Gilead and Arcus notched another win for their cancer program on Monday. GILD stock briefly hit a four-year high as RCUS stock gapped higher.

Via Investor's Business Daily

This Congressman Just Purchased 2 Stocks Which Consistently Increase Dividends ↗

November 28, 2022

Congressman Dwight Evans (D-PA) has represented Pennsylvania's Third Congressional District since 2019, and has made over 70 trades in the past three years. His top two traded investments are Intel...

Via Benzinga

Daily Stock Analysis: Roche Holding ↗

November 18, 2022

By my dogcatcher ideal, this is not a good time to buy Roche Holding AG shares based on their dividends for the coming year 2022-23.

Via Talk Markets

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Gives Emergency Use Nod To Roche's Monkeypox Test ↗

November 16, 2022

Via Benzinga

Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage ↗

November 15, 2022

Via Benzinga

Roche Inks Second Drug Discovery Deal With Jnana Therapeutics ↗

November 15, 2022

Via Benzinga

The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October

November 15, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones...

Via TheNewswire.com

Topics ETFs Stocks

FDA Grants Conditional Approval To First Antibody Drug Conjugate From ImmunoGen For Pretreated Ovarian Cancer ↗

November 15, 2022

Via Benzinga

Why Is Cassava Sciences (SAVA) Stock Up Today? ↗

November 14, 2022

Today's big move in Cassava Sciences and SAVA stock has many investors watching this company's trials closer than ever.

Via InvestorPlace

Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads ↗

November 14, 2022

The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads.

Via Investor's Business Daily

Roche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate Lingers ↗

November 14, 2022

Via Benzinga

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

November 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...

Via FinancialNewsMedia

Why Is Biogen (BIIB) Stock Up Today? ↗

November 14, 2022

Biogen (BIIB) stock is rising higher on Monday after Roche's (RHHBY) Alzheimer's drug didn't perform well in a clinical trial.

Via InvestorPlace

Roche's Alzheimer's Drug Fails In Phase 3; Here's The Fallout For Biogen, Lilly, Prothena And Others ↗

November 14, 2022

Biogen rose on Roche's Alzheimer's failure as a potential competitor drops off the map.

Via Investor's Business Daily

The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group's Most-Active List In October ↗

November 14, 2022

The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022.

Via Benzinga

Roche's Another Alzheimer's Hopeful Flops In Phase 3 Program, Second Trial Setback Within Months ↗

November 14, 2022

Via Benzinga

< Previous 1 2

...

15 16 17 18 19 20 21 22 23

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.